Document Type
Oral Presentation
Location
Oxford Conference Center, Oxford MS
Event Website
https://oxfordicsb.org/
Start Date
7-4-2025 3:00 PM
Description
Herbal and dietary supplements (HDS) are commonly used by consumers, and some have been linked to liver injury severe enough in some cases to result in transplantation and death. The U.S. Drug Induced Liver Injury is funded by the NIH to study liver injury from supplements. The DILIN investigators have identified many supplements linked to liver injury, as well as risks for the development of hepatotoxicity. The Network has also observed temporal trends in the occurrence of supplement related liver injury, some that parallel regulatory actions. In order to use these observations to promote consumer protection and supplement safety, the DILIN has embarked upon a collaboration with the FDA Human Foods Program - Office of Dietary Supplement Programs (FDA/HFP/ODSP) and its Human Foods Program Complaint System (formerly CAERS – which was the CFSAN Adverse Event Reporting System) to launch a sentinel surveillance program for supplement associated liver injury. The surveillance is expected to give the FDA timely information on potentially injurious products that may precipitate action to protect consumers.
Recommended Citation
Navarro, Victor, "An Update from the U.S. Drug Induced Liver Injury Network and Plans for Sentinel Surveillance for Supplement Induced Liver Injury" (2025). Oxford ICSB. 9.
https://egrove.olemiss.edu/icsb/2025_ICSB/Schedule/9
Publication Date
April 2025
Accessibility Status
Screen reader accessible, Searchable text
Included in
An Update from the U.S. Drug Induced Liver Injury Network and Plans for Sentinel Surveillance for Supplement Induced Liver Injury
Oxford Conference Center, Oxford MS
Herbal and dietary supplements (HDS) are commonly used by consumers, and some have been linked to liver injury severe enough in some cases to result in transplantation and death. The U.S. Drug Induced Liver Injury is funded by the NIH to study liver injury from supplements. The DILIN investigators have identified many supplements linked to liver injury, as well as risks for the development of hepatotoxicity. The Network has also observed temporal trends in the occurrence of supplement related liver injury, some that parallel regulatory actions. In order to use these observations to promote consumer protection and supplement safety, the DILIN has embarked upon a collaboration with the FDA Human Foods Program - Office of Dietary Supplement Programs (FDA/HFP/ODSP) and its Human Foods Program Complaint System (formerly CAERS – which was the CFSAN Adverse Event Reporting System) to launch a sentinel surveillance program for supplement associated liver injury. The surveillance is expected to give the FDA timely information on potentially injurious products that may precipitate action to protect consumers.
https://egrove.olemiss.edu/icsb/2025_ICSB/Schedule/9